Dialysis patients face a hidden heart risk that standard checkups often miss. Now, a single blood protein called SVEP1 may spot trouble earlier and more accurately than the tools doctors use today.
This matters because people on maintenance hemodialysis have very high rates of heart attacks, strokes, and other major cardiovascular events. Traditional risk calculators, built for the general public, fall short in this group. That leaves many patients and families feeling uncertain about their true risk.
Here’s the twist: a protein you’ve likely never heard of—SVEP1—stood out from more than 6,000 proteins tested. It rose to the top in two separate groups of dialysis patients and, by itself, outperformed the usual clinical risk scores.
This doesn’t mean this treatment is available yet.
Think of SVEP1 like a smoke alarm in a house. Traditional risk factors are like checking for visible smoke, but SVEP1 may detect the smoldering embers before flames appear. It’s a signal that shows up in the blood and seems to track with heart trouble over time.
The biology is still being untangled, but one clue stands out. SVEP1 is a very large protein—about 390 kilodaltons—that is unlikely to be cleared by the kidneys. That may help it persist in the bloodstream of dialysis patients, making it a more stable signal. Network analyses also point to complement pathways, a part of the immune system, as part of the story.
The research team analyzed 6,287 circulating proteins in 1,048 people on hemodialysis from the Chronic Renal Insufficiency Cohort (CRIC), following them for up to 14 years. They then validated the findings in a second group from the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease study (PACE), with 7 years of follow-up. Proteins were measured shortly after dialysis started and again one year later.
In CRIC, 149 proteins were linked to major heart events at a false discovery rate below 5%. After stricter correction for multiple comparisons, 22 proteins remained significant, and several validated in PACE. These included SVEP1, Complement component C7, R-spondin 4, Tenascin, Fibulin-3, and Fibulin-5. Among them, SVEP1 had the strongest statistical signal.
SVEP1’s performance was notable. In CRIC, each doubling of SVEP1 levels was tied to a 60% higher risk of major heart events over the study period. In PACE, the pattern held. For predicting events within two years, SVEP1 alone achieved an AUC of 0.72 in CRIC and 0.73 in PACE—numbers that mean it correctly identified risk more often than not. When pooled across both cohorts, SVEP1 reached an AUC of 0.79, surpassing traditional risk models that included troponin T and NT-proBNP.
But there’s a catch. These results come from observational data, which can show links but not prove cause. The models were tested in specific dialysis cohorts, and real-world performance may vary.
Experts note that SVEP1’s size and behavior in kidney failure make it an unusual and intriguing marker. It seems to add information beyond the usual suspects like troponin and natriuretic peptides. That suggests there may be new pathways to target for prevention, though more work is needed to understand the biology.
For patients on dialysis and their caregivers, this research offers a hopeful signal: better risk prediction may be on the horizon. If validated in future studies, a SVEP1 blood test could help doctors tailor prevention strategies—such as closer monitoring, medication adjustments, or lifestyle support—based on a clearer picture of individual risk. Talk to your care team about your current heart risk assessment and whether new tests may become available.
The study has important limitations. It was observational, and the protein measurements were taken at specific time points after dialysis started. The cohorts were well-characterized but may not represent all dialysis patients. Larger, prospective studies are needed to confirm whether measuring SVEP1 improves outcomes.
What happens next? Researchers will need to replicate these findings in diverse populations and test whether acting on SVEP1 levels changes patient outcomes. Mechanistic studies are also planned to explain how SVEP1 influences heart risk in kidney failure. Until then, this work points to a promising new direction in cardiovascular risk prediction for people on dialysis.
